Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy
Diabetes/Metabolism Research and Reviews · 2025-10 · 41 (7)
DOI: 10.1002/dmrr.70091 ↗At a glance
Übersichtsarbeit in Diabetes/Metabolism Research and Reviews, published online on 2025-10-09. Written by Aaron W Michels and 3 co-authors. Institution: Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Major MEDLINE topics: Diabetes Mellitus, Type 1, Immunotherapy. Cited 6 times so far (Crossref); 151 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIDDK NIH HHS, Sanofi.
Topics: Diabetes mellitus
Abstract (original language)
Disease‐modifying therapies have been used to treat the underlying causes of autoimmune diseases for over half a century. However, until recently, type 1 diabetes (T1D), the autoimmune form of diabetes, had not entered this therapeutic landscape. The approval of teplizumab, an anti‐CD3 monoclonal antibody and the first disease‐modifying therapy for use in individuals with preclinical T1D, has caused a major shift in the way healthcare providers can treat the T1D disease course. In this review, we discuss the chronic autoimmune nature of T1D and provide an overview of disease‐modifying therapies that are under investigation to target the autoimmune mechanisms in T1D to preserve residual beta‐cell function and prevent disease progression. The considerations for implementing these therapies into clinical practice are also discussed.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Children's Hospital of Richmond, Virginia Commonwealth University, Richmond, Virginia, USA.
- Cardiff University, Cardiff, UK.
Funding
- NIDDK NIH HHS
- Sanofi
Cite
APA
Michels, A. W., Gottlieb, P. A., Nelson, B., & Dayan, C. (2025). Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy. Diabetes/Metabolism Research and Reviews, 41(7). https://doi.org/10.1002/dmrr.70091
Vancouver
Michels AW, Gottlieb PA, Nelson B, Dayan C. Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy. Diabetes/Metabolism Research and Reviews. 2025;41(7). doi:10.1002/dmrr.70091
BibTeX
@article{Michels2025,
author = {Michels, Aaron W and Gottlieb, Peter A and Nelson, Bryce and Dayan, Colin},
title = {Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2025},
volume = {41},
number = {7},
doi = {10.1002/dmrr.70091}
}
EUVIMED